Senses Disorder TRIZ Cases

Injecting these stem cells into the subretinal space replaces damaged tissue without triggering proliferative vitreoretinopathy complications.

Three-stage cytokine regimen produces viable NK cells, resolving low yield and functional compromise in existing expansion methods.

Angiogenin agonists stimulate muscle mass and strength by reversing myostatin regulatory effects.

Novel GPR40 modulating compounds regulate insulin secretion and enhance glucose uptake through AMPK pathway activation.

Substituted pyrazolo-quinazoline compounds inhibit protein kinases to disrupt aberrant mitosis in cancer cells.

ShK peptides target Kv1.3 channels to treat dry eye and uveitis without steroid-induced vision loss.

Antibody targeting discontinuous epitope in HCMV glycoprotein gB AD1 region achieves high neutralizing capacity at lower dosages, reducing side effects.

Diluting a high-oil pre-concentrate reduces energy input and time loss while maintaining chemical stability for large-volume production.

Selective sulfone compounds activate CB2 receptors to treat inflammation and pain without triggering psychoactive effects.

Novel amino alcohol derivative acts as an S1P receptor agonist to deliver potent immunosuppressive activity.

Computational design identifies peptides that displace CLIP from MHC molecules to modulate immune cell function.

Trianzine derivatives inhibit Src family kinases, addressing insufficient therapeutic agents for cancer.

Formula I compounds inhibit PERK activation to reduce CHOP expression and mitigate noise-induced hearing loss.

Modifying CpG dinucleotide content in the RPE65 coding sequence reduces immunogenicity while maintaining therapeutic efficacy.

A scAAV2-shmTOR-SD vector delivers shRNA to suppress mTOR expression in retinal cells.

Antibodies targeting HIF-1α block hypoxia-inducible factor activity to treat refractory retinal diseases by reducing angiogenic factors.

Retinol eye compositions stimulate corneal epithelial cells to produce endogenous hyaluronic acid.

Modifying the purine ring structure reduces toxicity while maintaining antiviral efficacy against adenovirus.

Merging corticosteroids with kinin B2 receptor antagonists reduces pain while minimizing adverse gastrointestinal effects.

Topical dicyanopyridines selectively activate adenosine A1 receptors to reduce intraocular pressure without affecting hemodynamic parameters.

Sortilin crystal structure enables precise ligand identification via computer-aided modeling, preventing ternary complex formation.

Imidamide analogs target the unique substrate binding pocket of sphingosine kinases to achieve selective enzyme inhibition and improved oral bioavailability.

Amino-substituted fused pyridine derivatives resolve the contradiction between potency and selectivity in PI3K inhibition.

Pyrimidinone compounds modulate phosphoinositide 3-kinase activity, resolving the trade-off between treatment reliability and compound complexity.

Mucus-penetrating nanoparticles overcome mucoadhesion to deliver drugs effectively, ensuring therapeutic efficacy in treating diseases.

Glutarimide derivatives reduce eosinophil counts to treat diseases while avoiding corticosteroid side effects.

Antibodies recognizing KTPAF50 resolve low diagnostic specificity by detecting molecular markers for lung cancer treatment.

C16:1n7 palmitoleate composition reduces tear osmolarity and restores meibomian gland function to treat chronic dry eye disease.

A fusion polypeptide combines mitochondrial targeting and nuclear export signals to deliver DNA-binding proteins into mitochondria.

Segmenting the CFH-to-F13B locus into distinct gene regions resolves the contradiction between comprehensive genetic coverage and analytical complexity.

Segmenting erythropoietin isolates tissue protective domains, resolving the contradiction between cellular protection and unwanted erythropoietic effects.

Humanized anti-TNF-α antibodies use CDR grafting onto human frameworks to reduce immune response while maintaining binding affinity.

Triazolium salt compounds enhance water solubility while maintaining antithrombotic activity against PAR1 for treating deep vein thrombosis.

Segmented polyamine lipids maintain serum stability and undergo pH-dependent structural changes to enhance lung-specific siRNA delivery efficiency.

Fraction of Melissa officinalis leaf extract reabsorbs middle ear effusion and reduces mucosa thickness.

Nitrooxy prostaglandin amides lower intraocular pressure while minimizing ocular side effects via localized chemical substitution.

Genetically modified cells express transgenes to provide local immunosuppression, reducing systemic immune suppression risks.

Topical 2'-fucosyl-lactose restores physiological osmolarity to stabilize the tear film, addressing hyperosmolarity-induced dry eye syndrome.

Compounds inhibit plasma kallikrein to block the intrinsic coagulation pathway and reduce thrombin generation.

Specific heterocyclic structures increase metabolic stability and p21 promoter induction while minimizing adverse P450 enzyme interactions.

Novel quinoline derivatives block the fibronectin receptor alpha-5-beta-1 to inhibit angiogenesis.

Anilinopiperazine derivatives inhibit protein kinases via local quality design, resolving the trade-off between broad CDK activity and target selectivity.

Antibodies and siRNA agents modulate epidermal growth factor receptor signaling to treat myopia by regulating eye axial elongation.

Squalane and light mineral oil provide a stable, preservative-free delivery system that eliminates tissue damage from conventional eye drops.

Specific bacteriophages phiEF7H, phiEF19G, and phiEF14H1 eliminate drug-resistant Enterococcus bacteria while sparing healthy tissue.

Composite lipid microemulsions with shear-thinning polymers reduce ocular burning while maintaining visual clarity.

A dietary supplement combining copper and zinc glycinate with natural vitamin E to strengthen retinal health.